Stifel raised the firm’s price target on MacroGenics to $29 from $17 and keeps a Buy rating on the shares. The firm continues to believe patient over-enrollment into TAMARACK, coupled with management’s commentary and actions, read positively ahead of a now-confirmed ASCO disclosure. The firm’s increased price target mostly reflects a higher view of vobra-duo odds of success and higher U.S. peak sales estimates, the analyst noted.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on MGNX:
- MacroGenics Provides Update on Corporate Progress and 2023 Financial Results
- MacroGenics price target raised to $24 from $12 at BTIG
- MacroGenics to Participate in Upcoming Investor Conferences
- MacroGenics price target raised to $23 from $12 at Barclays
- MacroGenics Announces Date of Fourth Quarter 2023 Financial Results Conference Call
